器官移植受者发生的皮肤鳞状细胞癌中的肿瘤免疫微环境
The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients.
作者信息
Zilberg Catherine, Lyons James Guy, Gupta Ruta, Ferguson Angela, Damian Diona Lee
机构信息
Department of Dermatology, The University of Sydney at Royal Prince Alfred Hospital, Sydney, Australia.
Centenary Institute, The University of Sydney, Sydney, Australia.
出版信息
Ann Dermatol. 2023 Apr;35(2):91-99. doi: 10.5021/ad.22.175.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the most common malignancy in immune-suppressed organ transplant recipients (OTRs). Whilst rates of other malignancies (both cutaneous and non-cutaneous) are elevated in this population, the increase is far less striking. This suggests that cSCC must be a highly immunogenic tumor. The tumor immune microenvironment is altered in cSCC from OTRs. It has reduced anti-tumor properties and instead provides an environment that facilitates tumor growth and survival. Understanding the composition and function of the tumor immune microenvironment in cSCC from OTRs is useful for prognostication and therapeutic decisions.
摘要
皮肤鳞状细胞癌（cSCC）是免疫抑制器官移植受者（OTR）中最常见的恶性肿瘤。虽然该人群中其他恶性肿瘤（包括皮肤和非皮肤恶性肿瘤）的发病率有所升高，但升高幅度远没有那么显著。这表明cSCC必定是一种高度免疫原性的肿瘤。OTR的cSCC中肿瘤免疫微环境发生了改变。它的抗肿瘤特性降低，反而提供了一个促进肿瘤生长和存活的环境。了解OTR的cSCC中肿瘤免疫微环境的组成和功能，有助于进行预后判断和治疗决策。
相似文献
1
The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients.
Ann Dermatol. 2023 Apr;35(2):91-99. doi: 10.5021/ad.22.175.
2
Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression.
JAMA Dermatol. 2023 Sep 1;159(9):923-929. doi: 10.1001/jamadermatol.2023.2029.
3
Degree of differentiation of cutaneous squamous cell carcinoma: a comparison between a Swedish cohort of organ transplant recipients and immunocompetent patients.
Dermatol Pract Concept. 2018 Oct 31;8(4):330-336. doi: 10.5826/dpc.0804a18. eCollection 2018 Oct.
4
Altered density, composition and microanatomical distribution of infiltrating immune cells in cutaneous squamous cell carcinoma of organ transplant recipients.
Br J Dermatol. 2018 Aug;179(2):405-412. doi: 10.1111/bjd.16477. Epub 2018 May 10.
5
Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: A multicenter, prospective cohort study.
Am J Transplant. 2018 May;18(5):1220-1230. doi: 10.1111/ajt.14537. Epub 2017 Nov 22.
6
Variants at the OCA2/HERC2 locus affect time to first cutaneous squamous cell carcinoma in solid organ transplant recipients collected using two different study designs.
Br J Dermatol. 2017 Oct;177(4):1066-1073. doi: 10.1111/bjd.15618. Epub 2017 Sep 8.
7
Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients.
World J Transplant. 2021 Mar 18;11(3):54-69. doi: 10.5500/wjt.v11.i3.54.
8
Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients.
J Immunother. 2010 Jun;33(5):538-46. doi: 10.1097/CJI.0b013e3181cc2615.
9
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma.
NPJ Precis Oncol. 2020 Jun 3;4:13. doi: 10.1038/s41698-020-0119-9. eCollection 2020.
10
New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma.
Cell Tissue Res. 2016 Sep;365(3):691-702. doi: 10.1007/s00441-016-2457-z. Epub 2016 Jul 14.
引用本文的文献
1
Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response.
bioRxiv. 2024 Dec 4:2024.12.03.626669. doi: 10.1101/2024.12.03.626669.
2
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).
Cells. 2024 Sep 26;13(19):1615. doi: 10.3390/cells13191615.
3
The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review.
Cancers (Basel). 2024 Aug 21;16(16):2904. doi: 10.3390/cancers16162904.
4
A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.
Commun Biol. 2024 Jan 5;7(1):26. doi: 10.1038/s42003-023-05639-8.
本文引用的文献
1
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.
J Natl Compr Canc Netw. 2022 Apr;20(4):406-416.e11. doi: 10.6004/jnccn.2022.7009.
2
Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance.
Clin Cancer Res. 2022 Apr 14;28(8):1712-1723. doi: 10.1158/1078-0432.CCR-21-3746.
3
Risks of Multiple Skin Cancers in Organ Transplant Recipients: A Cohort Study in 2 Administrative Data Sets.
JAMA Dermatol. 2021 Dec 1;157(12):1447-1455. doi: 10.1001/jamadermatol.2021.4148.
4
Tumor-Associated Macrophages in Tumor Immunity.
Front Immunol. 2020 Dec 3;11:583084. doi: 10.3389/fimmu.2020.583084. eCollection 2020.
5
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.
6
Plasmacytoid dendritic cells in dermatology.
An Bras Dermatol. 2021 Jan-Feb;96(1):76-81. doi: 10.1016/j.abd.2020.08.006. Epub 2020 Nov 21.
7
Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region-Comparison between solid organ transplant recipients and immunocompetent patients.
Head Neck. 2021 Mar;43(3):884-894. doi: 10.1002/hed.26546. Epub 2020 Nov 27.
8
A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Oncologist. 2021 Feb;26(2):133-138. doi: 10.1002/onco.13539. Epub 2020 Oct 15.
9
LAG-3: from molecular functions to clinical applications.
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001014.
10
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma.
NPJ Precis Oncol. 2020 Jun 3;4:13. doi: 10.1038/s41698-020-0119-9. eCollection 2020.
Zotero 插件